what is the difference between retatrutide and tirzepatide vs. Tirzepatide: Next-Gen GLP-1 Showdown Retatrutide vs Tirzepatide (Research Comparison)

Research from major clinical trials shows that participants who discontinued GLP-1 therapy regained an average of 5070% of their lost weight within 12 months

The most recent meta-analyses grade it low-to-very-low certainty with no consistent overall increase (Liu and colleagues, meta-analysis, Ophthalmology , 2025

Participants in one 68-week trial, according to Novo Nordisk, lost almost 23% of their body weight on average

However, a potential increase in the risk of AEs was also noted, including a higher incidence of overall AEs, discontinuation due to AEs, hypoglycemia, and gastrointestinal complications

Early action can greatly help patients